Lobe Sciences (LOBE) Price & Analysis

Compare

12 Followers

LOBE Stock Chart & Stats

C$0.06

-C$0.01(-33.33%)

At close: Jan 08 4:00 PM EST

C$0.06

-C$0.01(-33.33%)

Day’s Range― - ―

52-Week RangeC$0.02 - C$0.11

Previous CloseN/A

Volume8.00K

Average Volume (3M)19.65K

Market Cap

C$18.86M

Enterprise ValueC$7.83M

Total Cash (Recent Filing)C$7.02M

Total Debt (Recent Filing)C$295.68K

Price to Earnings (P/E)―

Beta0.11

Next Earnings

May 04, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding269,487,120

10 Day Avg. Volume13,139

30 Day Avg. Volume19,648

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)2.94

Price to Sales (P/S)0.00

P/FCF Ratio-4.89

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Modest LeverageModest debt relative to equity (debt-to-equity ~0.19 TTM) reduces near-term financing pressure for an early-stage biotech. Lower leverage preserves optionality for R&D funding, partnerships, or milestone-based financing and reduces bankruptcy risk over the medium term.

Improving Cash Flow TrendTTM free cash flow shows improvement versus the prior annual period, suggesting operational progress or cost control. If sustained, this directional improvement can extend runway, lessen near-term dilution needs, and make the company a more credible partner for licensing or collaborations.

Strategic Focus In Mental Health/CNSA concentrated strategy on mental health/CNS and psychedelic-related therapeutics targets a large unmet medical need and growing scientific and regulatory interest. This niche can attract specialized investors, research collaborations, and licensing opportunities if clinical milestones are met.

Bears Say

No Revenue And Ongoing LossesTTM results show no product revenue and material operating losses (EBIT ~ -$5.0M; net loss ~ -$4.5M). Without revenue, the company relies on external capital or deals to fund operations, increasing execution risk and making long-term viability contingent on successful clinical progress or financing events.

Persistent Cash BurnOperating and free cash flows are substantially negative (~ -$1.75M TTM) and have been cash-burning for multiple years. Continued negative cash generation constrains R&D investment timing, forces recurring fundraising, and raises the probability of dilutive financings that can impair shareholder value.

Historical Equity InstabilityReported equity volatility and prior negative equity (2023–2024) point to past dilution or recapitalizations. This history increases the likelihood of future dilutive financings or weakened covenant positions, reducing investor protections and signaling structural balance-sheet fragility.

Lobe Sciences News

Lobe Sciences Names Mirza Rahimani as Chief Financial Officer

Lobe Sciences ( ($TSE:LOBE) ) has issued an announcement. Lobe Sciences has promoted Mirza Rahimani to Chief Financial...

6d ago

Lobe Sciences Ramps Up R&D on Psilocin-Based Therapeutic as Cash Position Remains Solid

The latest update is out from Lobe Sciences ( ($TSE:LOBE) ). Lobe Sciences reported first-quarter fiscal 2026 results...

1M ago

Lobe Sciences Bolsters Board with Capital Markets Expert as It Builds on 2025 Momentum

Lobe Sciences ( ($TSE:LOBE) ) just unveiled an announcement. Lobe Sciences has strengthened its board of directors with...

2M ago

Lobe Sciences Strengthens Balance Sheet and Refocuses Pipeline After Leadership Overhaul

Lobe Sciences ( ($TSE:LOBE) ) has issued an update. Lobe Sciences reported a substantial improvement in its fiscal...

2M ago

Lobe Sciences Strengthens Financial Position with Debt Settlement

Lobe Sciences ( ($TSE:LOBE) ) has issued an announcement. Lobe Sciences Ltd. has completed a debt settlement involving...

5M ago

Lobe Sciences Strengthens Financial Position with Debt Settlement

Lobe Sciences ( ($TSE:LOBE) ) has provided an announcement. Lobe Sciences Ltd. has completed a debt settlement by...

5M ago

Lobe Sciences Strengthens Balance Sheet with Strategic Debt Settlement

The latest update is out from Lobe Sciences ( ($TSE:LOBE) ). Lobe Sciences Ltd. has announced a strategic...

5M ago

Lobe Sciences to Present New Therapy for Cluster Headaches at 2025 Conference

Lobe Sciences ( ($TSE:LOBE) ) has shared an update. Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. are set...

6M ago

Lobe Sciences Strengthens Board with New Appointment

Lobe Sciences ( ($TSE:LOBE) ) has provided an announcement. Lobe Sciences Ltd. has appointed Marco Mastrodonato to its...

6M ago

Lobe Sciences Settles Directors’ Fees with Common Shares

Lobe Sciences ( ($TSE:LOBE) ) has provided an update. Lobe Sciences Ltd. announced the settlement of outstanding directors’...

7M ago

LOBE FAQ

What was Lobe Sciences’s price range in the past 12 months?

Lobe Sciences lowest stock price was C$0.02 and its highest was C$0.11 in the past 12 months.

What is Lobe Sciences’s market cap?

Lobe Sciences’s market cap is C$18.86M.

When is Lobe Sciences’s upcoming earnings report date?

Lobe Sciences’s upcoming earnings report date is May 04, 2026 which is in 50 days.

How were Lobe Sciences’s earnings last quarter?

Currently, no data Available

Is Lobe Sciences overvalued?

According to Wall Street analysts Lobe Sciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lobe Sciences pay dividends?

Lobe Sciences does not currently pay dividends.

What is Lobe Sciences’s EPS estimate?

Lobe Sciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lobe Sciences have?

Lobe Sciences has 269,487,120 shares outstanding.

What happened to Lobe Sciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Lobe Sciences?

Currently, no hedge funds are holding shares in TSE:LOBE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lobe Sciences

Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.